Simulation can be used to model the impact of new pharmaceutical products on patient care pathways and service design, facilitating their adoption by the market.
Using simulation to inform commissioning decisions to introduce
B-natriuretic peptide testing to the diagnostic pathway for
heart failure.
Read more
SIMUL8 was used to make the case for funding Wafarin treatment for all new patients at risk of developing a stroke cause by Atrial Fibrillation demonstrating that this approach would save over $1.5m.
See the Press Coverage
SIMUL8 now offers a new service for Clinicians and Drug Companies. The simulation offering helps pharmaceutical companies understand how their product fits with the real-life delivery of healthcare, and helps clinicians understand the impact of the product on patient outcomes, treatment regimes and budgets as well as how to re-deploy resources to fit with any impact on service design.